Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors,primary/secondary prophylaxis and complications observed under normal clinical practice

Abstract

We analyzed the principal risk factors of venous thromboembolism (VTE) (immobilization, recent surgery and previous VTE), prophylaxis with low-molecular weight heparin (LMWH) and complications (i.e. severe bleeding, recurrence and death). Patients with advanced cancer under palliative care (PC) and with VTE, were reviewed during the three years before the study. 71 Patients were diagnosed with VTE. 88.7% were outpatients. The risk factors present were: immobilizations in 28 patients (39.4%), recent surgery in 5 (7%) and previous VTE in 23 (32.5%). Prophylaxis was used in 4 (14.3%) patients with immobilization, no patient with recent surgery, and 10 (43.4%) patients with previous VTE. After diagnosis, all patients received treatment with LMWH in therapeutic dosage. The complications observed were: 6 recurrences (8.5%), 11 VTE-related deaths (15.5%), and bleeding events occured in 8 cases (11.3%), 4 (5.6%) of whom suffered severe bleeding; of these patients, 3 (4.2%) died as a result of the bleeding events. In PC patients with advanced cancer, VTE is a serious complication that conditions control of symptoms. The presence of other risk factors, immobilization and previous VTE, is common and LMWH prophylaxis is limited in clinical practice. The risks vs benefits of anticoagulation need to be counterbalanced.

Keywords

venous thromboembolism advanced cancer palliative care

Get full access to this article

View all access options for this article.

References

1 Lee AY Levine MN . Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I17–I21.

2 Johnson MJ Walker ID Sproule MW Conkie J . Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 1999; 21: 51–54.

3 Rickles FR Levine M Edwards RL . Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237–248.

4 Johnson MJ Sproule MW Paul J . The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999; 11: 105–110.

5 Monreal M Falga C Valdes M Suárez C Gabriel F Tolosa C . Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4: 1950–1956.

6 Noble SI Shelley MD Coles B Williams SM Wilcock A Johnson MJ . Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9: 577–584.

7 Johnson MJ Sherry K . How do palliative physicians manage venous thromboembolism. Palliat Med 1997; 11: 462–468.

8 Noble SI Finlay IG . Have palliative care teams’ attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005. J Pain Symptom Manage 2006; 32: 38–43.

9 Geerts WH Heit JA Clagett GP Pineo GF Colwell CW Anderson FA . Prevention of venous thromboembolism. Chest 2001; 119(Suppl 1): 132S–175S.

10.

10 Geerts WH Pineo GF Heit JA Bergqvist D Lassen MR Colwell CW . Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S–400S.

11.

11 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657–662.

12.

12 Mandala M Falanga A Piccioli A Prandoni P Pogliani EM Labianca R . Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194–204.

13.

13 Buller HR Agnelli G Hull RD Hyers TM Prins MH Raskob GE . Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S–428S.

14.

14 Noble SI Finlay IG . Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005; 19: 197–201.

15.

15 Noble SI Hood K Finlay IG . The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med 2007; 21: 473–476.

16.

16 Monreal M Zacharski L Jimenez JA Roncales J Vilaseca B . Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2: 1311–1315.